HC Wainwright reaffirmed their buy rating on shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock.
Armata Pharmaceuticals Price Performance
Shares of ARMP opened at $2.68 on Tuesday. The stock has a market cap of $96.96 million, a P/E ratio of -1.17 and a beta of 0.80. Armata Pharmaceuticals has a 1-year low of $1.93 and a 1-year high of $4.48.
Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.13). Research analysts forecast that Armata Pharmaceuticals will post -1.02 EPS for the current fiscal year.
Armata Pharmaceuticals Company Profile
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Featured Articles
- Five stocks we like better than Armata Pharmaceuticals
- What is Put Option Volume?
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
